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AN ERK-DEPENDENT SIGNALING PATHWAY REGULATED BY MIRS 
CONTRIBUTES TO AN AGING-RELATED DECREASE IN SMOOTH MUSCLE 
CONTRACTILITY BY INHIBITING CALDESMON PHOSPHORYLATION 
YI XING 
ABSTRACT 
 This project focused on extracellular signal-regulated kinase (ERK) and focal 
adhesion proteins related to ERK activity, and found a novel signaling pathway 
contributing to aging-related defects in smooth muscle contractility.  
Previous members of our lab have used ERK inhibitors to demonstrate the role of 
ERK in smooth muscle contraction. Dr. Nicholson used the ERK inhibitor FR 18024 and 
noted that, in the presence of this inhibitor phenylephrine (PE) induced a higher stress 
increase in young mouse aortas compared to old aortas. Inhibition of the kinase ERK 
abolished this difference. He also quantitated ERK phosphorylation, a marker of ERK 
activation in PE-stimulated aortas from both young and aged mice and found a significant 
lower level of phosphorylated-ERK (p-ERK) in aged mouse aortas. I was interested in 
determining the substrate of ERK that is affected in aging. Caldesmon (CaD) is one of the 
known substrates of ERK in smooth muscle. More importantly, CaD, as an actin-binding 
protein, inhibits cross-bridge formation by blocking the interaction between actin and 
myosin. Thus, I tested the hypothesis that, caldesmon phosphorylation is inhibited in 
aged mouse aortas. 
To determine the mechanism by which regulation of ERK activation changes with 
age, the role of micro-RNAs (miRs) in the regulation ERK phosphorylation was 
	
	 vi 
investigated. Transfection of miR-137 and -34a into A7r5 cells resulted in a significantly 
lower level of p-ERK in response to the phorbol ester DPBA. Further, together with my 
collaborators I found that transfection of miR-137 and -34a led to significantly decreased 
focal adhesion protein levels in A7r5 smooth muscle cells, such as paxillin and src. To 
confirm whether focal adhesion proteins contribute to the impairment of agonist-induced 
ERK phosphorylation, paxillin siRNA and src inhibitor were used. The results showed 
that paxillin is required for the phosphorylation of ERK1 and ERK2 and src is required 
for ERK2 phosphorylation. 
In conclusion, age-related increases in miR-137 and -34a decrease ERK 
phosphorylation via downregulation of paxillin and src. The decrease in ERK 
phosphorylation leads to a decrease in CaD phosphorylation and inhibits contraction. 
Thus, the thin filament-coupled pathway in differentiated vascular smooth muscle is 
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1.1.1. Smooth Muscle Contraction. 
Smooth muscle, along with skeletal muscle and cardiac muscle, makes up the 
muscle tissue of human body. Smooth muscle cells are mainly found in internal organs, 
such as blood vessels, gastrointestinal tract, and respiratory system (Pollard et al., 2017). 
The contraction of smooth muscle cells plays critical roles in regulating the body’s 
internal environment by generating force (Widmaier et al., 2014). For example, regular 
contraction of vascular smooth muscle is responsible for keeping the normal blood 
pressure and pushing the blood flow forward to organs downstream (Pollard et al., 2017). 
Although the three types of muscle function differently, the contraction basically 
depends on cross-bridge cycling. Ca2+ are well accepted as regulating all types of muscle 
contraction through variable signaling pathways. However, several labs have shown that 
there are multiple pathways with differing Ca2+ requirements that regulate contraction in 
smooth muscle. One such pathway is an ERK-dependent pathway in the regulation of 
smooth muscle contraction, which warrants investigation. 
1.1.1.1. Ca2+-dependent Muscle Contraction. 
In relaxed skeletal muscle cells, tropomyosin and troponin cooperate to block 
myosin from interacting with actin in the thin filament and, thus, inhibit contraction. This 
blocking effect can be eliminated by increases in the cytosolic calcium concentration. 
Ca2+ binds troponin, causing a conformational change that exposes the binding sites for 




In smooth muscle cells, it has been well established that increased calcium also 
promotes force generation through triggering cross-bridge cycling while the mechanism 
is different. Different from regulating actin availability in skeletal muscle cells, calcium 
controls myosin availability in smooth muscle cells. When cytosolic Ca2+ increases, it 
binds to calmodulin and the Ca2+-calmodulin complex binds to myosin light chain kinase 
(MLCK). Then myosin is phosphorylated by MLCK and is able to bind to actin filament 
to initiate cross-bridge cycling (de Lanerolle and Paul, 1991; Harnett et al., 2005; Walsh, 
1991). 
Though the Ca2+-calmodulin-MLCK pathway has been described as the 
predominant pathway regulating smooth muscle contraction (Horowitz et al., 1996), 
some examples of disassociation between force levels and myosin light chain (MLC) 
phosphorylation levels indicate the existence of other regulatory pathways, in which 
caldesmon plays critical roles (Huang et al., 2003; Lee et al., 2000). Caldesmon (CaD), is 
somewhat analogous to the troponin complex in skeletal muscle cells, functioning as a 
blocker to prevent the interaction between actin and myosin. CaD has an NH2-terminal 
myosin-binding domain as well as a COOH-terminal actin-binding domain which allows 
CaD to bind to both actin and myosin. Velaz et al. has demonstrated that the interaction 
between C-terminal of CaD and actin has an inhibitory effect on actomyosin ATPase 
activity (Velaz et al., 1990). Huang et al. indicated that this inhibition was reversed by 
Ca2+-calmodulin complex (Huang et al., 2003). Additionally, Lee et al. pointed out that 
due to the ability of CaD to bind both actin and myosin, the tethering of actin to myosin 




the actomyosin ATPase activity (Lee et al., 2000). They also showed that using a 
competitor to the N-terminal of CaD for myosin binding caused displacement of CaD and 
led to disinhibition of actomyosin activity. Therefore, it appears that binding of CaD to 
actin and to myosin both have inhibitory effects on smooth muscle cells contraction. 
 
1.1.1.2. The ERK Signaling Pathway-involved Regulation of Smooth Muscle 
Contraction. 
The inhibitory effect of CaD blocking the binding of myosin to actin is removed 
by ERK-induced CaD phosphorylation at Ser 789 (Patchell et al., 2002). Horowitz et al. 
has emphasized the importance of the link between protein kinase C and actin-based 
regulatory mechanisms in the physiological realities of the smooth muscle cells 
(Horowitz et al., 1996). There was evidence that the activated ERK signaling pathway 
increases cross-bridge cycling and triggers smooth muscle contraction by removing the 
actin inhibition (Li, Moon, et al., 2003; Xiao and Zhang, 2002). In smooth muscle cells, 
activation of MEK, a dual activity kinase, phosphorylates ERK on a tyrosine and 
threonine and leads to ERK activation (Brozovich et al., 2016; Ping et al., 1999). 
Activated ERK has been shown to phosphorylate CaD on Ser 789 and remove the 
inhibitory effect of CaD on the interaction between actin and myosin (Gerthoffer et al., 
1996; Gerthoffer et al., 1997; Hai and Gu, 2006; Kordowska et al., 2006; Li, Je, et al., 
2003; Li et al., 2009; Saphirstein et al., 2015). Previous studies have utilized ERK 
activation to trigger contraction of rat aortic smooth muscle (Ok et al., 2014; Zhao et al., 




1.1.2. Aging-related Decreases in Aortic Smooth Muscle Contractility. 
Aging has been reported to negatively affect the contractility of several smooth 
muscles, such as airway smooth muscle, gastrointestinal smooth muscle, and vascular 
smooth muscle. Hayashi and Toda proposed in 1980 that the excitatory effects from the 
stimulation of H1-receptor in rabbit trachea smooth muscle decreases with aging (Hayashi 
and Toda, 1980). In 1983, Simpkins et al. showed that the contractile responses of rat 
aorta to both KCl and norepinephrine decreased with aging (Simpkins et al., 1983). In 
2004, Bitar and Patil demonstrated that gastrointestinal smooth muscle cells from old rats 
exhibited limited length distribution and decreased contractility which may due to the 
effects of aging on several signaling pathways (Bitar and Patil, 2004). Moreover, the 
carbachol-induced myogenic responses in the colon of a non-human primate model were 
reported to be reduced in aged animals (Tran and Greenwood-Van Meerveld, 2014). In 
general, the relationship between aging and smooth muscle contractility has been most 
studied in vascular smooth muscle since 1970s.  
The aorta, the main and largest artery in human body, distributes oxygenated 
blood to the whole body, which is important to keep the organs downstream working 
normally. To maintain the normal functions of aorta, compliance related to the 
extracellular matrix and contractility of smooth muscle cells are required (Silver et al., 
1989; Tuna et al., 2012; Wagenseil and Mecham, 2009). Since the 1970s, several labs 
have investigated the relationship between aging and aortic smooth muscle contractility. 
Cohen and Berkowitz demonstrated in 1976 that the contractile responses to serotonin, 




1979, Carrier et al. confirmed the negative effect of aging on norepinephrine-induced 
contraction in rat aorta (Carrier et al., 1979). Moreover, evidence showed that aging has a 
negative effect on pressure-induced ERK activation in the rat aorta (Rice et al., 2005). 
Therefore, it is possible that diminished ERK activation plays a role in the aging-related 
defects in smooth muscle contractility. 
 
1.2. Thesis Rationale 
Due to the importance of the aorta in maintaining the normal function of the 
human body and preventing the development of several cardiovascular diseases, the 
mechanism underlying the defective contractile activities of aorta with aging is worthy of 
investigation. Although the ERK signaling pathway has been shown to contribute to 
contraction of various types of smooth muscle cells, the relationship between ERK 
activation and aging-related defects in mouse aorta remains elusive. This study aimed at 
determining the effect of aging on aortic smooth muscle contractility in the mouse and 




This project aims at testing two hypotheses: (1) Aging causes defects in smooth 
muscle contraction in mouse aorta; (2) The ERK signaling pathway is responsible for an 




Control aortic tissues were obtained from C57BL/6J mice (The Jackson 
Laboratory; #000664) and aged aortic tissues were from C57BL/6 mice (National 
Institute on Aging), which are the most widely used strains in a variety of research fields, 
including cardiovascular biology research (The Jackson Laboratory). Due to its genetic 
similarity to human, mouse provides valuable information that can be applied to human. 
The other reason why the mouse was selected as the experimental model for this study is 
its relatively short life expectancy. Mice develop 150 times faster than human beings in 
the first month after birth. The maturational rate of mice decreases after the first month 
while still 45 times faster than human beings in 1-6 months and 25 times faster after 6 
months (Flurkey et al., 2007). The quick maturation of mice allows several hypotheses 
related to aging to be tested in a relatively short time (Vanhooren and Libert, 2013). 
According to Figure 1, C57BL/6J mice at 3 months of age are comparable to mature 
adults and able to be used for tests. Mice from 24 to 28 months of age are appropriate for 





Figure 1. Comparison of age ranges between C56BL/6J mice and human beings. 
From: Flurkey et al., 2017 
The A7r5 cell line is a good model for research on the physiology and 
pathophysiology of vascular smooth muscle (Torres et al., 2016). The main value of the 
A7r5 cell line depends on its ability to convert between a nonsynthetic, nonmigratory 
“contractile” phenotype and a migratory “synthetic” phenotype (Salloum et al., 2005). 
 
1.4. Approaches 
Comparison was performed between young adult (3 months of age) and aged (24-




done to the mice. The stress (force/cross sectional area) increase was used to characterize 
the contractility of smooth muscle, and western blot analysis was performed to determine 






2.1. Ethical Approval 
 All procedures were performed in accordance to protocols approved by the 
Institutional Animal Care and Use Committee of Boston University (Permit Number: 
A3316-01). The animals were maintained according to the guidelines set out by the NIH 
Guide for the Care and Use of Laboratory Animals, and were obtained and used in 
compliance with federal, state, and local laws. Aortic tissues were extracted quickly after 
euthanization by isoflurane inhalation.  
 
2.2. Aortic Tissue Preparation 
After administration of a euthanizing dose of isoflurane, mice (young, 3-4 
months; aged, 24-29 months) were pinned to a foam board. The skin of the mouse was 
cut from abdomen to the top of thorax. Then the abdominal wall under the ribcage was 
opened and fixed to the foam board with pins. The tips of the scissor were always up to 
prevent damage to the organs. Organs, such as liver and lungs were removed to expose 
the aorta. 
After excision of the aorta, it was rinsed 4-5 times in ice-cold tissue-collecting 
buffer (TCB; modified Krebs solution, in mM: 154 NaCl, 5.4 KCl, 1.2 MgSO4, 10 
MOPS, 5.5 glucose, and 1.6 CaCl2; pH = 7.4) to wash away the blood around the tissue. 
The lab has found that blood is toxic to smooth muscle and can induce contraction 
(Bulter et al., 1996). Then the aortic tissue was placed in ice-cold TCB and carefully 




thoracic arch and abdominal aorta were discarded. Each thoracic aortic tissue was evenly 
cut into 2 rings (4–6mm in length; marked as “upper thoracic” and “lower thoracic”) for 
contraction experiments. Thin rings were cut from both sides of these 4–6mm rings (3 
rings in total; marked as “UT”, “MT”, and “LT”) and kept in TCB for wall thickness 
measurements. For further biochemical analyses, aortic rings were frozen in freezing 
solution (10 mM dithiothreitol and 10% trichloroacetic acid dissolved in a dry ice-
acetone slurry) immediately after removing from the organ bath (Marganski et al., 2005). 
 
2.3. Cell Culture 
A7r5 rat aortic smooth muscle cells (ATCC, Manassas, VA, USA) were cultured 
in DMEM (4 mM L-glutamine, 4500 mg/l glucose, 1 mM sodium pyruvate, and 1500 
mg/l sodium; ATCC, Manassas, VA, USA) with 10% FBS (Gibco, Grand Island, NY, 
USA), 100 I.U./ml penicillin and 100µg/ml streptomycin (ATCC, Manassas, VA, USA). 
When the A7r5 cells were 80-90% confluent, they were either split into new large plates 
or seeded into 6-well plates for transfection. Both DMEM and phosphate buffered saline 
(PBS; ATCC, Manassas, VA, USA) were prewarmed in a 37°C water bath and trypsin-
EDTA solution (0.1% porcine trypsin and 0.04% EDTA; Sigma-Aldrich, St. Louis, MO, 
USA) was prewarmed at room temperature. After the old media was aspirated out, PBS 
was used to wash away excess old media. In order to detach the cells from the bottom of 
the plates, 1ml trypsin-EDTA solution was added to each plate. Then the cells were 
incubated for 5 minutes in the CO2 incubator (37°C with 5% CO2; VWR International, 




falcon tubes and centrifuged at 10,000 g for 4 minutes. The supernatant was removed and 
DMEM was added to resuspend the cells. Cells then were transferred to new plates for 
further use.  
 
2.4. Transfection of Cells 
A7r5 cells were seeded into 6-well plates and grown to confluency at a density of 
1´105 cells/well. The transfection reagent was Lipofectamine RNAiMAX reagent from 
Invitrogen (Carlsbad, CA, USA). The following miR mimics from Ambion (Invitrogen, 
Carlsbad, CA, USA) were used: Negative Control #1 (mirVana™ miRNA mimic), hsa-
miR-137-3p (mirVana™ miRNA mimic), and hsa-miR-34a-5p (mirVana™ miRNA 
mimic). RNAiMAX reagent, miR mimic and control miR were mixed with Opti-MEM® 
I reduced serum medium (2% serum, 2.4 g/l sodium bicarbonate; Gibco, Life 
Technologies, Carlsbad, CA, USA), respectively, For one 6-well plate (3 for miR mimi 
and 3 for control miR), 3.75 µl of miR mimic or control miR was added to 146.25 µl of 
Opti-MEM, and 18µl of RNAiMAX was added to 2682 µl of Opti-MEM. The mixtures 
were incubated at room temperature for 5 minutes. Then RNAiMAX mixture was evenly 
added to both the miR mimic mixture and the control miR mixture and incubated for 
another 20 minutes at room temperature. Old media in 6-well plates was aspirated out 
and PBS was used to wash away excess media. Control miR mixture and miR mimic 
mixture were added to cells, respectively, and Opti-MEM® was added to each well to 
make the final volume 2.5 ml. Cells were transfected in the hood and then incubated in 




2.5. Ex vivo aortic stress measurement 
Aortic rings were mounted with two triangular wires with 0.01-inch diameter. The 
lower wire was fixed by going through a hook and the upper triangular wire was 
connected to the force transducer to measure the force produced by contraction and a 
micrometer to adjust the stretch on the aortic rings. Once mounted, the aortic rings were 
incubated in an organ bath containing 37°C, oxygenated (95% O2, 5% CO2) 
physiological salt solution (PSS; Krebs solution, in mM: 120 NaCl, 5.9 KCl, 11.5 
dextrose, 25 NaHCO3, 1.2 NaH2PO4, 2.5 CaCl2, and 1.2 MgCl2; pH = 7.4). Stretch was 
measured quantitatively by the model 300C Dual-Mode Lever Arm System (Aurora 
Scientific, Aurora, Ontario, Canada) and data were recorded in Chart Software (AD 
Instruments, Sydney, New South Wales, Australia).  
Before the measurements, calibration was performed by setting the force 
produced by the hook and two triangular wires as “0 g” and the force produced by the 
addition of a 1-gram weight as “1 g”. After being strung up, each aortic strip was 
stretched to optimal length (1.7 times of original diameter; about 1.4 g force produced) 
and left to equilibrate for 45 minutes in Krebs solution. To start, 96mM KCl solution 
(modified Krebs solution, in mM: 30 NaCl, 96 KCl, 11.5 dextrose, 25 NaHCO3, 1.2 
NaH2PO4, 2.5 CaCl2, and 1.2 MgCl2) was diluted with Krebs solution at a 1:2 dilution 
ratio to prepare a 51 mM KCl solution for experimental use. The 51 mM KCl solution 
was prewarmed in a 37°C water bath and added into the organ bath to confirm vascular 
smooth muscle contractility and viability. After the 15-minute depolarization by the 51 




Krebs solution for 15 minutes. Then the 15-minute depolarization with KCl and washing 
with Krebs solution were repeated once followed by a 15-minute incubation in Krebs 
solution. PE was then added to stimulate contraction. Measurements of force generated 
were collected at baseline before the 2nd depolarization with the 51 mM KCl solution, 15 
minutes after the adding the 51 mM KCl solution for the 2nd time, and 10 minutes after 
adding PE. 
Ex vivo aortic stress in this study could be measured as the amplitude of force 
normalized to cross sectional area: Stress = ∆F/(2DL), where ∆F is the amplitude of the 
force response to the stretches, D is the wall thickness of aortic strips, and L is the axial 
length of aortic strips. 
 
2.6. Measurement of Wall Thickness 
One drop of NucBlue® Live ReadyProbes® Reagent (Invitrogen, Carlsbad, CA, 
USA) was added to each tube (one ring per tube). The rings were incubated in the dark 
for at least 20 minutes. Nikon ECLIPSE TE-2000-E microscope (Nikon, Tokyo, Japan) 
was used to visualize the fluorescence and NIS-Elements Advanced Research 3.2 
software (Nikon, Tokyo, Japan) was used for thickness measurements. The magnification 
was set as 20x. 
The aortic rings were put on slides and hydrated with TBS. The slides were 
placed on the stage of microscope and moved around until the ring was under the light. 
The images were taken when they were in focus and 4-6 images were required for each 




20-30 measurements per ring. The average of these measurements would be taken as the 
wall thickness of the ring. The wall thickness of upper thoracic was calculated by taking 
an average of thickness of “UT” and thickness of “MT”. The thickness of lower thoracic 
would be the mean of thickness of “MT” and thickness of “LT”. 
 
2.7. Protein Extraction 
Aortic rings were homogenized in tissue lysis buffer (62.5 mM Tris, 2% SDS, and 
10% sucrose supplemented with Halt™ protease & phosphatase inhibitor cocktail). To 
start, Quick-frozen aortic strips were washed 5 times with 1.54 mg/ml dithiothreitol 
(DTT) in acetone for 5 minutes each time. Then aortic rings were transferred to 
Precellys® lysing kits tube (Bertin Technologies, Montigny-le-Bretonneux, France) for 
soft tissue homogenizing (one ring per tube) along with 40 µl tissue lysis buffer. Aortic 
rings were homogenized 8 times at 1,500 rpm for 25 seconds each time with the 
Precellys® 24 tissue homogenizer (Bertin Technologies, Montigny-le-Bretonneux, 
France) kept at 4°C. Samples were placed on ice for 2 minutes between cycles. Tissue 
lysates were cleared by centrifugation for 10 minutes at 13,000 rpm, 4°C. The 
supernatant was transferred to new labeled tubes and stored at -80°C for further use. 
A7r5 cells were lysed in cell lysis buffer (62.5 mM Tris, 2% SDS, and 10% 
sucrose supplemented with protease inhibitor cocktail). To start, Opti-MEM® including 
transfection reagent, miR mimic or miR control was aspirated out and cells were washed 
with cold PBS twice. To each well of the 6-well plates, 20 µl cell lysis buffer was added. 




into new labeled tubes. The cell lysates were vortexed 5 times for 10 seconds each time 
with Mini Vortexer MV1 (IKA, Wilmington, NC, USA) and put back on ice for 2 
minutes after each vortex. Then the cell lysates were cleared by centrifugation for 10 
minutes at 13,000 rpm, 4°C. The supernatant was transferred to new labeled tubes and 
stored at -80°C for further use. 
 
2.8. Lowry Assay for Protein Concentration 
Protein samples and bovine serum albumin standards (BSA standards; in µg/µl: 0, 
0.75, 1.5, 3, 6) were thawed on ice. The experiments were run in triplicate in clean and 
dry 96-well plates (Fig. 2). For the standard curve, 1 µl tissue or cell lysis buffer and 1 µl 
BSA standard solutions were added in lanes 1-3 and rows B-F. 0 BSA standard solution 
and lysis buffer were also added to row A and set as “blank” (BLK) as required for the 
computer program to read properly. For the protein samples, 1 µl ddH2O and 1 µl protein 





Figure 2. Layout of the Lowry Assay. 
The following reagents from Bio-Rad Laboratories (Hercules, CA, USA) were 
used for the colorimetric assay: DCTM Protein Assay Reagent A (abbreviated as reagent 
A below), DCTM Protein Assay Reagent S (abbreviated as reagent S below), DCTM 
Protein Assay Reagent B (abbreviated as reagent B below). Appropriate amount of 
reagent A and reagent S were mixed at a ratio of 50:1. 10 µl A/S mixture and 80 µl 
reagent B were added into each well. The 96-well plate was covered by aluminum foil 
and put on the rocker at room temperature for 20 minutes to develop the color. 
The protein colors were read by a SynergyTM H1 microplate reader (BioTek 
Instruments, Winooski, VT, USA) and data analysis was performed by Gen 5 microplate 
reader and imager software (BioTek Instruments, Winooski, VT, USA). The 





2.9. Western Blotting 
N-ethylmaleimide (NEM) and 2-4x sample buffer (SB) were mixed at a 1:1 ratio. 
Proteins then were mixed with NEM/SB mixture at a 1:1 ratio. The samples were mixed 
well by vortexing followed by a quick spin down and denatured by heating at 95°C for 5 
minutes in the Standard Heatblock (VWR International, Radnor, PA, USA) with caps on 
lids. Then the protein samples were vortexed again followed by a quick spin down.  
For gel preparation, mini-gel glass plates (for 1mm gel) were assembled and put 
into the casting stand. The following components were mixed gently for 2 of the 10% 
separating gels: 6.7 ml ddH2O, 4.0 ml lower gel buffer, 5.3 ml acrylamide, 80 µl 10% 
ammonium persulfate (APS), and 8 µl TEMED. After the gel mixture was added, 400 µl 
ddH2O was added on the top of each gel. The separating gel was kept at room 
temperature for 30 minutes to solidify. The stacking gel was made by mixing the 
following components: 3.0 ml ddH2O, 1.25 ml upper gel buffer, 0.75 ml acrylamide, 30 
µl 10% ammonium persulfate (APS), 10 µl TEMED. The comb was inserted into the 
stacking gel quickly and the gel was kept at room temperature to solidify. If saved for 
further use, the gel was wrapped with wet tissue paper first and then plastic wrap and 
stored at 4°C. 
After the gel was solidified, the apparatus was assembled and filled with 1x 
running buffer (diluted from 10x running buffer stock with ddH2O). The comb was taken 
out and then the protein samples were loaded. The blank lanes were loaded with the 
NEM/SB mixture. The gel was run at a constant voltage of 60V for about 2.5 hours until 




nitrocellulose membranes (Bio-Rad Laboratories, Hercules, CA, USA) with HoeferTM TE 
70 semi-dry transfer unit (Amersham Biosciences, Chiltern, England). The blotting pads 
(VWR International, Radnor, PA, USA) were pre-soaked as follows: 2 in Anode I buffer, 
1 in Anode II buffer, 2 in Cathode buffer. The membrane and gel were rinsed in Anode II 
buffer. The “sandwich” was assembled in the following order (from bottom to top): 2 
blotting pads pre-soaked with Anode I buffer, 1 blotting pad pre-soaked with Anode II 
buffer, membrane, gel, and 2 blotting pads pre-soaked with Cathode buffer. Then a small 
amount of Cathode buffer was poured on the “sandwich” before transfer. The transfer 
process was performed at 20 mV, 120 mA (for 1 gel) or 240 mA (for 2 gels) for 1.5 
hours. After the transfer, all molecular weight markers were checked to confirm that all 
proteins have been transferred successfully and the membrane was kept at room 
temperature to dry for 30 minutes. Then the proteins were blocked by incubating the 
membrane in Odyssey® blocking buffer (LI-COR Biosciences, Lincoln, NE, USA) for 1 
hour at room temperature.  
The membranes were cut into targeted regions based on the molecular weight of 
proteins of interest. Appropriate dilutions of primary antibodies were added to 
membranes, respectively, and stored in sealed bags. The membranes were incubated in 
primary antibodies overnight at 4°C and washed in tris-buffered saline with Tween 20 
(TBST; diluted from 20x TBS stock solution) for 5 times and 5 minutes each time. Then 
the membranes were incubated in secondary antibodies at room temperature for 1 hour in 




Protein bands were visualized on Odyssey (LI-COR Biosciences, Lincoln, NE, 
USA) and densitometric analysis was performed with the Odyssey 2.1 software (LI-COR 
Biosciences, Lincoln, NE, USA). Intensity was adjusted for display purposes but all 
analysis was performed on the raw data. For analysis of protein expression, bands of 
interest were normalized to GAPDH or total protein. 
 
2.10. Chemicals, Reagents and Antibodies 
The following chemicals were purchased from Fisher Scientific (Rockingham, 
NH, USA): sodium chloride (NaCl), potassium chloride (KCl), dextrose anhydrous(D-
glucose), sodium phosphate monobasic (NaH2PO4), sodium bicarbonate (NaHCO3), 
dithiothreitol (DTT), trichloroacetic acid (TCA), acetone, and sucrose. The magnesium 
sulfate (MgSO4), ammonium persulfate (APS), MOPS sodium salt, and the α-
adrenoreceptor agonist were obtained from Sigma-Aldrich (St. Louis, MO, USA). The 
calcium chloride (CaCl2) and magnesium chloride (MgCl2) were purchased from VWR 
International (Radnor, PA, USA). The sodium dodecyl sulfate (SDS) was obtained from 
ICN Biomedicals (Aurora, OH, USA). A protease & phosphatase inhibitor was purchased 
from Thermo Scientific (Waltham, MA, USA) and the protease cocktail was acquired 
from Roche (Indianapolis, IN, USA). The acrylamide was Protogel® 30% (w/v) 
Acylamide: 0.8% (w/v) Bis-Acrylamide Stock Solution (37.5:1) from national 
diagnostics (Atlanta, GA, USA) and the TEMED was from Bio-Rad Laboratories 




The following primary antibodies were used: ERK (mouse, 1:500) and phospho-
ERK (rabbit, 1:1000) from Cell Signaling Technology (Danvers, MA, USA); FAK 
(rabbit, 1:200) and src (rabbit, 1:500) from Santa Cruz Biotechnology (Dallas, Texas, 
USA); src (mouse, 1:500) from Abgent (San Diego, CA, USA); paxillin (mouse, 1:500) 
from BD Biosciences (San Jose, CA, USA); MEKK1 (rabbit, 1:500), phospho-caldesmon 
(rabbit, 1:250), and GAPDH (rabbit, 1:20,000) from Sigma-Aldrich (St. Louis, MO, 
USA); phospho-caldesmon (rabbit, 1:250) from Millipore (Darmstadt, Germany). 
Secondary antibodies used were IRDye® 680 RD Goat anti-Rabbit (1:1000) and IRDye® 
800CW Goat anti-Mouse (1:1000) from LI-COR Biosciences (Lincoln, NE, USA). 
 
2.11. Preparation of Stock Solutions 
NEM solution was 2.5% (w/v) NEM and 33% (v/v) BPB-saturated glycerol in 
ddH2O. 2-4x sample buffer was 2% (v/v) glycerol, 4.4% (w/v) SDS, 300mM Tris, and 
125mM DTT dissolved in ddH2O. Both NEM and 2-4x SB stocks were stored at -20°C.  
Lower gel buffer was 0.4% (w/v) SDS dissolved in 1.5M Tris-HCl solution (pH = 
8.8) and upper gel buffer was 0.4 (w/v) SDS in 0.5M Tris-HCl solution (pH = 6.8), both 
of which were stored at room temperature. 10% (w/v) APS solution was made by 
dissolving APS in ddH2O and stored at 4°C. 10x running buffer stock was made by 
dissolving 30g Tris, 144g glycine, and 10g SDS in 1000 ml ddH2O without adjusting pH 
and stored at room temperature. 
5x Anode I stock was 1.5 M Tris (pH = 10.4). 5x Anode II stock was 125 mM 




buffers were made by mixing 40 ml 5x stocks and 20 ml methanol and adding ddH2O 
until the final volume is 200 ml.  
20x TBS stock contained 3 M NaCl and 0.2 M Tris-HCl solution (pH = 7.5) and 
was autoclaved before being stored at 4°C. TBST was made by adding ddH2O to 50 ml 
20x TBS stock and 1ml Tween-20 until the final volume is 1000 ml and was put on 
stirrer for a better mix. 
 
2.12. Statistics 
All values are presented as mean ± S.E.M. Analysis was carried out using the 
GraphPad Prism (7.0) software (La Jolla, CA, USA). For biochemical analysis (of mRNA 
and protein expression) and stress comparisons, groups were compared using a Student’s 
t-test (two-tailed) or two-way ANOVA for parametric data. For grouped analyses, data 






3.1. Reduced agonist-induced contraction is seen in aged mouse aortas 
To investigate the effects of aging on contractility of the mouse aorta, I excised 
mouse aortas from both young and aged mice. The mouse aortic rings were stimulated by 
phenylephrine (PE) and the raw traces were recorded. Figure 3 shows the contraction of 
individual aortic rings from a young mouse (3 months old; Fig. 3A) and an aged mouse 
(28 months old; Fig. 3B). Both of these two aortic rings showed responses to potassium 
chloride (KCl). Also, both young and aged mouse aortas showed responses to increasing 
doses of PE but the response in aged mouse aorta (40% of KCl-induced contraction) is 





Figure 3. Contractility of mouse aortas decreases with aging. Original raw traces of 
aortic smooth muscle contraction in young (A) and aged (B) mouse aortas were recorded. 
Aortic rings were treated with increasing doses of PE after 2nd KCl-induced 
depolarization and a 15-minute equilibrium in Krebs solution. The concentration of PE 
(in µM) started from 0.01, then increased to 0.05, 0.1, 0.5, 1, 5, and 10 at last. The aortic 
rings were incubated in each concentration for 2 minutes. Forces generated by 
contraction were expressed as % of KCl-induced contraction. 
 
3.2. KCl-induced contraction does not significantly change with aging 
Since the PE-induced contraction in Fig. 3 was expressed as a % of the KCl-
induced contraction, I investigated KCl- and PE-induced contractions separately to 
confirm the effect of aging on each of them. KCl-induced contraction data were collected 
from the 2nd KCl-induced contraction of young and aged mouse aortas. Aortic smooth 
muscle contractility was expressed as stress increase (kPa) by normalizing the raw 
contraction data (expressed as force increase, g) to the length and wall thickness of aortic 
rings. The KCl-induced stress increase in young mouse aortas was 19.13 ± 1.244 KPa, n 
= 17 and the stress increase in aged mouse aortas was 19.2 ± 1.127 KPa, n = 14. The 
stress data demonstrated that there was no significant difference in smooth muscle 
contractility between young and aged mouse aortas (p = 0.9646) in response to KCl 





Figure 4. KCl-induced steady state contraction of mouse aortic tissue does not 
significantly change with aging. Mean of stress increase in young mouse aortas: 19.13 ± 
1.244, n = 17. Mean of stress increase in aged mouse aortas: 19.2 ± 1.127, n = 14. 
(unpaired two-tailed Student’s t test) 
	
3.3. PE-induced contraction is attenuated with aging  
To determine how aging affects aortic smooth muscle contractility in response to 
PE stimulation, I treated aortic rings from both young and aged mice with increasing 
doses of PE and analyzed stress increase data. Treatment of low concentrations of PE (10-
8 and 5x10-8 M) resulted in no significant difference (p = 0.9993 for 10-8; p = 0.2714 for 
5x10-8) in stress increase between young and aged mouse aortas. However, with 
increasing doses, the stress increase in aged mouse aortas was significantly lower than 
that in young mouse aortas (Fig. 5), which demonstrated that smooth muscle contractility 





Figure 5. PE-induced contraction is significantly lower in aged mouse aortas. Aortic 
rings from young (n = 6) and aged (n = 6) mice were treated with increasing doses of PE. 
Stress increase (KPa) data were calculated and used for statistical analysis. ****p < 
0.0001, ***p < 0.001, **p < 0.01, *p < 0.05 (2-way ANOVA) 
 
3.4. Downregulation of ERK phosphorylation contributes to age-related decrease in 
agonist-induced contraction in mouse aortas  
We and others have demonstrated that KCl-induced contraction is Ca2+-dependent 
while PE triggers not only the calcium-dependent pathway, but also another ERK 
signaling pathway, which requires less calcium (Fig. 6). However, the possible role of the 
ERK signaling pathway in the age-related defects in smooth muscle contractility has not 
been studied in mouse aorta. Since the KCl-induced contraction did not significantly 
change with aging while PE caused a significantly lower contraction in aged mouse 




the ERK signaling pathway was responsible for the reduced PE-induced contraction in 
aged mouse aortas. 
 
Figure 6. Overview of pathways regulating vascular tone. Figure from: Brozovich et 
al., 2016 
I began by following up Dr. Nicholson’s finding that diminished ERK activation 
is responsible for reduced contractility of aortic smooth muscle in aged mouse. Dr. 
Nicholson found that the novel ERK-selective inhibitor FR 18024 drastically attenuated 
the contractile effect of PE on both young and aged mouse aortas and most importantly, 
the inhibition of ERK activation resulted in no significant difference in stress increase 
between young and aged mouse aortas. To further establish the effect of aging on PE-




and aged mouse aortas stimulated with PE (10µM). Compared with young mouse aortas 
(2-fold increase from baseline), PE-induced ERK phosphorylation is significantly lower 
in aged mouse aortas (1.4-fold increase from baseline). 
 
3.5. Caldesmon regulation of smooth muscle contraction in response to PE 
stimulation is lost in aged mouse aorta 
My laboratory has previously shown that ERK phosphorylates caldesmon (CaD) 
in vascular smooth muscle, which leads to contraction by eliminating the inhibition of 
CaD on actin (Kordowska et al., 2006; Li, Je, et al., 2003; Li et al., 2009; Saphirstein et 
al., 2015). To investigate the role of CaD in age-related smooth muscle contractile 
dysfunction, I compared CaD phosphorylation in young and aged mouse aortas after PE 
(10 µM) stimulation. CaD phosphorylation significantly increased in the presence of PE 
(1.36-fold increase, p < 0.05) in young mouse aortas, while surprisingly, there was no 
significant change (p = 0.7595) in aged mouse aortas (Fig. 7), suggesting that the effect 





Figure 7. Phospho-caldesmon (p-CaD) does not significantly change after PE 
stimulation in aged mouse aortas. Aortic rings from young (n = 14) and aged (n = 12) 
mice were treated with PE (10 µM) for 10 minutes. Protein extracted from these frozen 
aortic rings were used to perform western blotting to quantitate CaD phosphorylation. *p 
< 0.05 (paired two-tailed Student’s t test) 
 
3.6. Increased miR-137 and -34a expression downregulate the expression of focal 
adhesion proteins which cause defective ERK signaling in A7r5 cells 
The question arises as to the mechanism by which agonist-induced ERK 
phosphorylation decreases with aging. My laboratory group has previously demonstrated 
that miR-137 and -34a increase with aging and are predicted, by reverse target prediction, 
to affect multiple genes that are related to ERK signaling (Nicholson et al., 2017). To 
investigate the possible role of these two miRs in age-related defects in agonist-induced 
ERK activation, others in my laboratory transfected A7r5 cells with miR mimics for miR-




deoxyphorbol 13-isobutyrate 20-acetate)-induced ERK phosphorylation after 72 hours of 
incubation. ERK phosphorylation was determined by western blotting and normalized to 
total ERK for statistical analyses. The results showed that transfection of both -34a and 
miR-137 significantly attenuated ERK activation in A7r5 cells. 
We then sought to figure out how ERK phosphorylation is affected by miR-137 
and -34a. Several proteins related to ERK signaling, including non-receptor tyrosine 
kinase src (miR-34a and miR-137), the focal adhesion proteins paxillin (miR-34a and 
miR-137), focal adhesion kinase FAK (miR-34a), and vinculin (miR-34a), and the MEK 
proteins MEK 1 (miR-34a) and MEKK 1 (miR-137), were predicted to be targets of miR-
137 and -34a (Nicholson et al., 2017). 
Others in my laboratory saw changes in mRNA levels of proteins mentioned 
above when cells were transfected with miR mimics. A7r5 cells were transfected with 
miR mimics for miR-137 (or -34a) and negative control miR for 24 hours for RNA 
analyses. Cells were lysed and RNA samples were analyzed by qRT-PCR. The results of 
qRT-PCR demonstrated that miR-34a caused reduction of mRNA levels of src, paxillin, 
FAK, and vinculin and that a miR-137 mimic induced decreases in src, paxillin, and 
MEKK 1 mRNA levels.  
To confirm that the changes in mRNA levels also lead to changes in protein 
expression in response to miR-137 (or miR-34a), I worked with Dr. Nicholson to repeat 
the transfection experiments and lysed the A7r5 cells 72 hours after transfection. Proteins 
were analyzed by western blotting. Consistent with the results of mRNA analyses, 




paxillin (31% less), and MEKK 1 (25% less) in A7r5 cells (Fig. 8A) and protein 
expression of paxillin (44% less), src (17% less), FAK (22% less) and Vinculin (31% 
less) were significantly downregulated after miR-34a transfection (Fig. 8B). 
 
Figure 8. Transfection with miR-137 and -34a significantly reduces the expression of 
several proteins related to ERK signaling in A7r5 cells. Protein expression levels of 
A7r5 cells transfected with miR-137 (n = 6) and -34a mimic (n = 9) were analyzed by 
western blot. (data collected by collaboration with Dr. Nicholson) ****p < 0.0001, ***p 




Having determined that both miR-137 and -34a downregulate src and paxillin in 
A7r5 cells, my laboratory next sought to investigate whether src and paxillin play causal 
roles in decreasing agonist-induced ERK signaling. Our lab members therefore tested 
whether interfering with src or paxillin influences agonist-induced ERK activation. 
Paxillin was knocked down by transfecting A7r5 cells with paxillin siRNA and this 
resulted in significant lower phospho-ERK 1 (p-ERK 1) and p-ERK 2 in A7r5 cells, 
suggesting that paxillin is required for phosphorylation of both isoforms of ERK. Src was 
inhibited by treating mouse aortic rings with a src inhibitor, PP2 and similarly, this 
significantly reduced ERK 2 phosphorylation in aortic tissue, suggesting that at least src 






4.1. Defective thin filament regulation is responsible for age-related weakness of 
mouse aorta 
In this study, my first main finding is that the aged mouse aorta shows decreased 
contractility compared to that of the young mouse aorta. To investigate the exact changes 
of aortic smooth muscle contractility with aging in response to different agonists, I 
analyzed the normalized contraction data, expressed as stress increases (force/cross 
sectional area; in KPa) by measuring the length and wall thickness of aortic rings. The 
results (Fig. 4) showed that the amplitude of the KCl-induced contraction did not 
significantly change with aging. Since it has been shown that KCl regulates vascular tone 
by affecting myosin phosphorylation in a calcium-dependent way (Brozovich et al., 
2016) (Fig. 2), I concluded that thick filament regulation of vascular tone was not 
affected with aging. However, in contrast, the aged mouse aortas show significant lower 
stress increases in response to PE stimulation (Fig. 5), suggesting that PE-specific 
signaling pathways might be responsible for age-related defect in aortic smooth muscle 
contractility. My laboratory group has previously shown that PE regulates vascular tone 
in multiple ways (Brozovich et al., 2016) (Fig. 2). One of them is through a calcium-
dependent pathway that regulates myosin activity (#1). This pathway is activated by KCl-
induced depolarization. There is also another pathway including ERK signaling which 
regulates vascular tone through actin (#3). With the conclusion that thick filament 




filament regulation of vascular tone is responsible for the age-related defect in smooth 
muscle contractility. 
 
4.2. Loss of ERK-mediated CaD phosphorylation contributes to reduced smooth 
muscle contractility in aged mouse aortas 
My second main finding in this study is discovering the mechanism by which 
ERK signaling decreases smooth muscle contractility with aging. My laboratory group 
previously found that inhibition of PE-induced ERK activation with the addition of an 
ERK inhibitor, leads to a significantly lower stress increase in mouse aortas. These 
results indicate that the ERK signaling pathway is required for normal contractility of 
mouse aortas. In addition, aging was associated with a decrease in PE-induced ERK 
activation, suggesting that defective ERK signaling plays a critical role in age-related 
smooth muscle weakness. 
In contractile cells, activated ERK has previously been shown to promote the 
phosphorylation of actin-binding protein, CaD and thus, alleviate the CaD-induced 
inhibition of the actin-myosin interaction (Hai and Gu, 2006; Kordowska et al., 2006; Li, 
Je, et al., 2003; Li et al., 2009; Saphirstein et al., 2015). In light of the association 
between aging and agonist-induced ERK phosphorylation, the relationship between aging 
and agonist-induced CaD phosphorylation warranted investigation. We report here that 
PE has no effect on CaD phosphorylation in age mouse aortas (Fig. 6), indicating that 
agonist-induced contraction of mouse aortas through CaD phosphorylation is lost with 




of smooth muscle contraction is responsible for the age-related defect in smooth muscle 
contractility of mouse aortas. 
As shown in figure 10, I conclude that with aging, ERK phosphorylation in 
response to PE stimulation is impaired and leads to defective smooth muscle contractility 
through the loss of CaD phosphorylation.  
 
4.3. Upregulation of miR-137 and -34a in aged mouse aortas decreases ERK 
activation due to downregulation of paxillin and src 
My last main finding is the mechanism by which ERK activation is regulated. 
Recently, many labs have studied the effects of miRs on ERK signaling pathway in many 
systems (Ding et al., 2018; He et al., 2018; Ma et al., 2018; Sun et al., 2019; Xiao et al., 
2018; Xu et al., 2012). In light of the finding of our lab that miR-137 and -34a increase 
with aging (Nicholson et al., 2017), I hypothesized that upregulation of miR-137 and -
34a might be responsible for decreased ERK activation in aged mouse aortas. A7r5 cells 
transfected with miR-137 or -34a mimicked the effects of aging on these two miRs and 
the increase in these two miRs significantly lowered the DPBA-induced ERK 
phosphorylation. Therefore, it is reasonable to conclude that age-related decreases in 
ERK activation are mediated by upregulation of miR-137 and -34a.  
Since miRs function via base-paring with mRNA, they are only able to 
downregulate protein expression, but not protein posttranslational modification. It is 
reasonable to postulate that some proteins mediate the effect of miRs on ERK 




predicted several proteins that are potential targets of miR-137 and -34a and also related 
to ERK phosphorylation, including non-receptor tyrosine kinase src (miR-34a and miR-
137), the focal adhesion proteins paxillin (miR-34a and miR-137), FAK (mir-34a), and 
vinculin (miR-34a), and the MEK proteins MEK 1 (miR-34a) and MEKK 1 (miR-137). 
To test the hypothesis that increased miR-137 and -34a downregulate the expression of 
some proteins which function as ERK kinases and thus inhibit ERK phosphorylation, 
A7r5 cells were transfected with miR-137 or -34a to mimic the effects of aging on these 
two miRs. Consistent with the results of reverse target prediction, miR-34a inhibits the 
expression of FAK, paxillin, src, and vinculin and miR-137 has an inhibitory effect on 
protein expression of paxillin, src, and MEKK 1.  
MEK 1, as an MAPK/ERK kinase, directly adds a phosphate group to ERK when 
activated. Similarly, MEKK 1, as an MEK kinase, can effect ERK phosphorylation by 
regulating MEK activation. The question arose as how other proteins regulate ERK 
activation. Paxillin has been shown to be able to act as an ERK scaffold by constitutively 
interacting with MEK and by binding to inactive ERK when phosphorylated at Tyr118 by 
src (Ishibe et al., 2003). Therefore, binding to important proteins in the ERK signaling 
pathway enables paxillin to affect ERK phosphorylation. In addition, the src-dependent 
paxillin phosphorylation at Tyr118 requires src to target to the focal adhesion, which is 
regulated by FAK (Wu et al., 2015). Also, FAK can directly interact with paxillin and 
this interaction leads to paxillin phosphorylation at Tyr 118, which requires 
phosphorylation of FAK at Tyr 397 (Turner, 2000). Additionally, FAK was shown to be 




studies (Hauck et al., 2002; Schwartz, 2001). Other labs have shown that MEK 1, MEKK 
1, paxillin, src, and FAK all have positive effects on ERK phosphorylation. Their 
findings are consistent with the results that upregulation of miR-137 and -34a inhibit 
ERK activation via decreased expression of these upstream proteins (Fig. 8). Vinculin has 
a sequence in its tail domain similar to the paxillin-binding region of FAK. The fact that 
both vinculin-knock out cells and the expression of vinculin with mutation in its tail 
region showed an increase in FAK-paxillin interactions is consistent with the proposal 
that the vinculin tail competes with FAK for paxillin binding thus regulates paxillin 
phosphorylation (Subauste et al., 2004). Interestingly, vinculin was also found to 
decrease with upregulated miR-34a in A7r5 cells which should lead to increase in ERK 
activation. To explain this controversial result, more studies are necessary to clarify the 
relationship between paxillin and vinculin. The diagrammatic representation of ERK’s 
relationships with these proteins suggested by McKay and Morrison and shown below is 
consistent with my results from the mouse aorta (Fig. 9). 
 
Figure 9. Diagrammatic representation of the regulation of ERK activation by 




With the results my laboratory group have obtained, the effects of these proteins 
on ERK activation warranted investigation. Since paxillin and src are postulated to be 
regulated by both miR-137 and -34a, my laboratory group focused on these two proteins 
only. A7r5 cells transfected with paxillin siRNA showed significantly lower ERK1/2 
phosphorylation than cells transfected with control siRNA. Inhibition of src activity in 
mouse aortic rings led to significantly less ERK2 phosphorylation. Thus, it appears that 
paxillin is required for the phosphorylation of both isoforms of ERK and src is required 
for ERK2 phosphorylation. 
Taking into consideration all results my lab has obtained, I conclude that 
signaling pathway such as that shown in figure 10 is responsible for aging-related defects 
in aortic smooth muscle contractility. With aging, the upregulation of miR-137 and -34a 
blocks expression of paxillin and src, which then results in decreased ERK activation. 
Decreases in ERK activation lead to a decreased CaD phosphorylation and thus, a 





Figure 10. A signaling pathway responsible for aging-related decrease in smooth 
muscle contractility. The dash arrow means unknown mechanism. The red inhibitory 
sign means negative effect and the black arrow means positive effect. 
 
4.4. Significance 
4.4.1. A weakened aorta with aging may be related to the development of 
aortic aneurysm. 
In this study, I found a new signaling pathway regulating smooth muscle 
contraction that is lost with age, leading to a weakening of the aorta. The weakened aorta 
with aging might lead to lethal diseases, such as aortic aneurysm. American Heart 




which causes death from rupture (American Heart Association, 2015). Aortic aneurysms 
are found to predominantly affect the elderly (Wohlauer and Eagleton, 2017). This points 
to the possibility that the sort of decreased contractility of the mouse aorta with aging 
reported here might be responsible for the development of aortic aneurysm in the elderly 
human. Since the discovery that thoracic aortic aneurysm (TAA) is highly familial, 
genetics of TAA have been widely studied (Brownstein et al., 2017). The missense 
mutations in ACTA2 and MYH11 genes were found to be associated with TAA (Guo et 
al., 2007; Liu et al., 2017; Milewicz et al., 2008; Pannu et al., 2007; Zhu et al., 2006). 
Surprisingly, the proteins that are encoded by these two genes are α-actin (encoded by 
ACTA2) and β-myosin heavy chain (encoded by MYH11) which are required for normal 
smooth muscle contractile function. This finding suggests that the maintenance of 
contractile function of aortic smooth muscle cells is essential for the protection against 
the development of TAA as has been suggested by others (Guo et al., 2013; Isselbacher 
et al., 2016; Milewicz et al., 2017; Prakash et al., 2010). 
 
4.4.2. Potential therapeutic targets are provided by our study. 
Surgical repair of the open aorta has been the only available treatment for TAA 
until the recent development of endovascular aortic aneurysm repair (EVAR) (Parodi et 
al., 1991). This new therapy has consistently decreased short-term mortality compared 
with open repair (Becquemin et al., 2011) and more importantly, is acceptable for the 
aged population who could not tolerate open repair. However, aging is still one of the risk 




receive any treatment, the complication and mortality rates for emergency surgery is 
exceedingly high (Wohlauer and Eagleton, 2017). Therefore, preventing the development 
of aortic aneurysm is beneficial to all age groups, especially the elderly. 
In this study, we found a signaling pathway regulating vascular tone that is 
defective with age. This finding is meaningful since it provides several potential targets 
for aortic weakness. Inhibition of miR-137 and -34a expression in the aged population 
may reverse the effects of these upregulated miRs on protein expression and 
phosphorylation downstream, and then reverse the phenotype. Similarly, increasing 
expression of src and paxillin may lead to higher ERK and CaD phosphorylation and thus 
eliminate the inhibitory effect on cross-bridge formation. Directly increasing ERK or 
CaD phosphorylation may also be a method to reverse aging-related aortic weakness. 
With all of these possible methods to increase aorta strength, it is possible to lower the 
possibility of developing aortic aneurysm, and thus decrease death rate. 
 
4.5. Limitations and future plans 
Though potentially exciting results were obtained in this study, there are still 
some limitations. According to the limitations, I made plans for future experiments. 
 
4.5.1. Changes when mice get super-aged need to be clarified. 
In this study, we define “aged” mice as 24-27 months of age, which correlates 
with human ranging 69-75 years of age (Flurkey et al., 2007). However, our lab has 




months of age. Possible changes might include changes in the amplitude of agonist-
induced contractions, protein expression and protein phosphorylation. With the fact that 
the human lifespan has increased due to better medical care, a new cut-off point beyond 
70 years of age should be more appropriate to define “old” (Jacobs et al., 2012). 
Therefore, mice around 29 months of age are worth being studied. The problem we are 
facing is that the survivorship drops off quickly after 24 months of age and reaches 50% 
at the age of 28 months (Flurkey et al., 2007). Much worse, even though mice live 
through 29 months of age, some of them are sick which might affect the contractility of 
the aorta, which make sample collection much more difficult.  
 
4.5.2. Some experiments using A7r5 cells should be repeated with mouse 
aortic rings. 
To mimic the upregulation of miR-137 and -34a in aged mouse aorta, we 
transfected A7r5 cells with miR mimics. Compared with transfection of miR mimics into 
A7r5 cells, it is more difficult to do tissue transfection since the aortic rings need to be 
kept alive in miR mimics-containing Krebs solution for 72 hours to show significant 
protein changes. Though the A7r5 cell line is a good model for study of smooth muscle 
contractility because of its ability to convert between a nonmotile “contractile” phenotype 
and a motile “synthetic” phenotype (Salloum et al., 2005), it is more convincing if we 





4.5.3. Animal testing is needed. 
In this study, all the results obtained were from either aortic tissue or the A7r5 cell 
line. The relatively new signaling pathway regulating smooth muscle contraction 
presented here is defective in aged mice, which leads to our proposal that by regulating 
miR-137 and -34a, expression of src and paxillin, and phosphorylation of ERK and CaD, 
it is possible to prevent the decrease of smooth muscle contractility or even reverse the 
weakened smooth muscle in aged mice. However, this new signaling pathway needs to be 
confirmed in animals before the miRs and proteins can be used as potential targets for 
new therapies. I would suggest inhibiting miR-137 (or -34a), or increasing the expression 
of paxillin, or increasing ERK (or CaD) phosphorylation in aged mice and measuring 
force generated by contraction. By comparing the stress increase of these “edited” aged 
mice with young mice and aged mice, we can know whether a weakened aorta can be 
reversed by affecting the new signaling pathway. In addition, doing the same to young 
mice and measuring the force when they reach 24 months of age is also suggested. 
Comparison of stress increases between young mice, “edited” aged mice, and regular 
adult aged mice will tell us whether defective contractility can be prevented by affecting 
the new signaling pathway. 
 
4.6. Conclusion 
I report here a potential signaling pathway that is defective with aging. Different 
from the traditional calcium-dependent pathway which regulates contraction through 




availability. I propose that with aging, miR-137 and -34a are upregulated which inhibits 
protein expression of src and paxillin. Lower src and paxillin levels with aging then cause 
less ERK phosphorylation. As a result of less ERK activation, CaD phosphorylation is 
also inhibited. Therefore, inactivated CaD remains inhibitory to the interaction between 
actin and myosin and inhibits contraction. Thus, this age-related signaling pathway 
provides exciting potential targets for new therapeutics that could make it possible to 
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